World Congress Insulin Resistance
DIABETES & CARDIOVASCULAR DISEASE

FREE LIVE INTERACTIVE ONLINE
December 3–6, 2020

LIVE VIRTUAL HOLLYWOOD

Exploring New Frontiers In Metabolism – Tomorrow’s Clinical Science Today

JOINTLY PROVIDED

ADMINISTERED BY:

#WCIRDC2020
Welcome.

It is my pleasure to invite you to the 18th Annual World Congress on Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC): Exploring New Frontiers in Metabolism — Tomorrow’s Clinical Science Today.

Following the restrictions imposed by the pandemic, the 18th Annual WCIRDC is going virtual! The live, interactive, online congress will take place on December 3–6, 2020 with free registration and 33.5 free CME/ABIM-MOC credits available. The 4 day live-Online conference will continue to be available On Demand for 90 days. Following each session, there will be a live, interactive Q&A. The end of each day will conclude with a live panel summary discussion and interactive Q&A.

Since its inception, the congress has become the premier global meeting dedicated to metabolism-obesity, diabetes, lipids, HTN, CKD, CVD, HF, and NAFLD. It provides an exclusive opportunity for practicing professionals, clinical and basic scientists, researchers, and other clinicians to collaborate on emerging scientific and management strategies. The WCIRDC faculty consists of distinguished global experts who link research to clinical practice in a bench-to-bedside approach that is unique to this state-of-the-art program.

The conference includes joint sessions with the journals Metabolism and Lancet Diabetes & Endocrinology. Sessions will cover COVID-19, Heart Disease in Women, Lipotoxicity, Fatty liver, Lipids & Atherosclerosis, Contemporary Approach to Management of DM, CKD, CVD & HF Focus on GLP1ra, SGLT2i, and CGM, Obesity-Adults and pediatrics addressing Diets and bariatric surgeries.

Special sessions: Point-Counterpoint: Etiology of Insulin Resistance, debate: T2D Medications With CV Benefits for T1D, the Cardiometabolic Center Alliance, ACC Position on Managing CVD in DM, Genetics of T2D & CVD, Cancer and Medications Impact on Metabolism, Advance Technologies, Future Therapies for Diabetes, and Lifestyle in Disease Management.

Although virtual, the 18th WCIRDC congress will continue to have a robust e-Poster Hall, Oral Abstract Presentations, and an attractive Exhibit Hall, as well as Industry Supported CME & non-CME programs that, similar to the faculty of the congress, will feature some the world’s best-known leaders and educators of their fields.

I look forward to having you join us for this exciting Live-Interactive-Online program on December 3–6, 2020!

Best regards,

Yehuda Handelsman, MD
Chair & Program Director
The World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC), now in its 18th year, is a unique and exciting multidisciplinary CME program. The Congress is the premier global meeting dedicated to diabetes, obesity, lipids, cardiovascular-kidney and liver disease linking basic research to clinical practice in pursuit of our theme: Exploring New Frontiers in Metabolism — Tomorrow’s Clinical Science Today.

This year, due to the pandemic, the Congress, originally planned for Los Angeles, goes virtual: Live-Interactive-Online over 4 days and will be available on demand for 90 days. For the first time, the registration will be free, including 33.5 CME & ABIM-MOC credits.

For nearly two decades, WCIRDC has brought researchers, physicians, clinicians, and other healthcare professionals together for a distinctive international program that bridges the latest developments from bench-to-bedside. “I heard it first at the Congress” is a frequent remark from the audience. WCIRDC offers attendees a unique experience to interact with the distinguished global faculty for a collaborative experience that explores the newest understanding of metabolic diseases and the development of future therapeutic modalities.

The Congress attracts state-of-the-art abstracts by young, up-and-coming researchers as well as recognized leaders from around the globe. The abstracts will be available for 90 days on the conference platform and published in Metabolism, a peer-reviewed journal, with over 40,000 unique monthly viewers worldwide, which is in the top 10% of endocrinology, diabetes, and metabolism journals.

Proceedings from the Congress are featured in global medical news venues such as Healio, Medscape, Endocrinology & Cardiology Today, Clinical Endocrinology News and more, while articles are being published in peer reviewed journals like Journal of Diabetes, Endocrine Practice, Metabolism, Diabetes & Vascular Disease Research, and others.

We welcome you to join us in this new phase of the Congress. We are looking forward to the same success, with you, in our new platform, just as we had in the past 17 years.

**PROGRAM DESCRIPTION**

The program is designed to evaluate the clinical and basic science aspects of diabetes, obesity, HTN, dyslipidemia, CVD, HF, CKD and related cardiometabolic conditions; focusing on basic science such as insulin resistance, hyperinsulinemia, fat, inflammation and clinical practice; understanding cardiometabolic conditions. The goal is to understand the pathophysiology of each condition and develop appropriate comprehensive clinical management plans.

Upon completion of this meeting, participants should be able to:
- Discuss COVID-19 and diabetes and Obesity
- Discuss Heart disease in women
- Describe the relationship between diabetes, obesity, and heart failure

**PROGRAM OBJECTIVES**

- Discuss The etiology of Insulin resistance
- Discuss T1D obesity and CVD
- Discuss the effect of lipotoxicity and the pathophysiology of CVD
- Discuss the role of obesity in the development of cardiometabolic conditions
- Explain the roles of diabetes in the development of micro & macrovascular conditions: kidney disease, retinopathy, neuropathy, CVD and strokes
- Provide comprehensive management of diabetes, addressing obesity, hypertension, dyslipidemia and hyperglycemia while focusing on preventing ASCVD
- Discuss the role of GLP1ra in the management of diabetes, obesity, and prevention of ASCVD
- Evaluate SGLT2i inhibitors role in reducing cardiovascular morbidity & mortality in patients with and without T2D and at risk for or established CVD
- Address SGLT2i role in managing patients with CKD and HFREF
- Explain the role of PCSK9 inhibitors in preventing CV morbidity in people with established ASCVD
- Discuss fatty liver disease and its relationship to diabetes and CVD
- Evaluate the impact on clinical practice of recent CVD, CHF & CKD outcome trials
- Evaluate the impact on clinical practice of lipid CV outcome trials, including IMPROVE-IT, FOURIER, REDUCE-IT, ODYSSEY-Outcomes
- Analyze the Cardiorenal Syndrome
- Examine the impact of Coagulation in diabetes in prevention of CVD and CVA
- Describe technology in monitoring and reducing DM & ASCVD

**TARGET AUDIENCE**

This educational initiative is designed for cardiologists, endocrinologists, internists, PCPs, diabetologists, OB/GYNs, pediatricians, gastroenterologists, oncologists, dietitians, nurse practitioners, physician assistants, pharmacists, and any other health care professionals who are interested in improving patients outcome.
### SESSION #1  
**LIPOTOXICITY: THE PATHOPHYSIOLOGIC LINK BEHIND THE CARDIO-METABOLIC SYNDROME**

**Chairs:** Ralph DeFronzo, MD • Robert Chilton, DO  

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker(s)</th>
<th>Affiliation</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:10 am</td>
<td>The Myocardium: Too Fat to be Fit</td>
<td>Robert Chilton, DO</td>
</tr>
<tr>
<td>8:30 am</td>
<td>Fatty Kidney: The Renal Manifestation of the Metabolic Syndrome</td>
<td>Ralph DeFronzo, MD</td>
</tr>
<tr>
<td>8:50 am</td>
<td>Nonalcoholic Fatty Liver Disease and Diabetes: Clinical Implications of “Foie Gras”</td>
<td>Kenneth Cusi, MD</td>
</tr>
<tr>
<td>9:10 am</td>
<td>The Beta Cell — Insulin Resistance Connection: A Fat Story?</td>
<td>Eric Ravussin, PhD</td>
</tr>
<tr>
<td>9:30 am – 9:50 am</td>
<td>Live Q&amp;A Panel Discussion</td>
<td></td>
</tr>
</tbody>
</table>

### SESSION #2  
**HEART DISEASE IN WOMEN**

**Chair:** Tracey McLaughlin, MD • Matthew Budoff, MD

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker(s)</th>
<th>Affiliation</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:50 am</td>
<td>Sex Differences in Coronary Artery Calcium and Long-term CV Mortality</td>
<td>Martha Gulati, MD</td>
<td>Paul Zimmet, AO, MD, PhD</td>
</tr>
<tr>
<td>10:10 am</td>
<td>Sex-Specific Differences in Risk Factors for Development of Heart Failure in Women</td>
<td>Gina Lundberg, MD</td>
<td>Howard Hodis, MD</td>
</tr>
<tr>
<td>10:30 am</td>
<td>Estrogen Replacement Atherosclerosis and CVD</td>
<td>Howard Hodis, MD</td>
<td>Paul Zimmet, AO, MD, PhD</td>
</tr>
<tr>
<td>10:50 am – 11:10 am</td>
<td>Live Q&amp;A Panel Discussion</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### SESSION #3  
**LANCET DIABETES & ENDOCRINOLOGY & 18 WCIRDC JOINT SESSION: COVID-19, DM & METABOLISM**

**Chair:** Marta Koch, PhD

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker(s)</th>
<th>Affiliation</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:55 am</td>
<td>Two Pandemics in Collision: COVID-19 and Diabetes</td>
<td>Paul Zimmet, AO, MD, PhD</td>
<td></td>
</tr>
<tr>
<td>12:15 pm</td>
<td>Managing Patients with Diabetes and COVID-19</td>
<td>Stefan Bornstein, MD</td>
<td></td>
</tr>
<tr>
<td>12:35 pm</td>
<td>Obesity and Metabolic Surgery During and Beyond COVID-19</td>
<td>Geltrude Mingrone, MD</td>
<td></td>
</tr>
<tr>
<td>12:55 – 1:15 pm</td>
<td>Live Q&amp;A Panel Discussion</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### SESSION #4  
**CME SYMPOSIUM**

**HEART FAILURE AND KIDNEY DISEASE: THE NEXT EPIDEMICS**

**Supported by and Educational Grant from AstraZeneca**

**Chairs:** Michael Miller, MD • Yehuda Handelsman, MD

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker(s)</th>
<th>Affiliation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:15 pm</td>
<td>Introduction</td>
<td>Yehuda Handelsman, MD, Chair</td>
<td>Maria Rosa Costanzo, MD</td>
</tr>
<tr>
<td>1:20 pm</td>
<td>Epidemiology and Traditional Management of HF and CKD</td>
<td>Mikhail Kosiborod, MD</td>
<td>Katherine Tuttle, MD</td>
</tr>
<tr>
<td>1:40 pm</td>
<td>The Future Is Here: Contemporary Approach to HF with a Focus on HFrEF</td>
<td>Mikhail Kosiborod, MD</td>
<td>Muthiah Vaduganathan, MD</td>
</tr>
<tr>
<td>2:00 pm</td>
<td>Revolution in the Management of Moderate to Severe CKD</td>
<td>Katherine Tuttle, MD</td>
<td></td>
</tr>
<tr>
<td>2:20 pm</td>
<td>Impact of Recent CVOTs on Contemporary Guidelines for HF and CKD</td>
<td>Katherine Tuttle, MD</td>
<td></td>
</tr>
<tr>
<td>2:40 pm – 3:10 pm</td>
<td>Panel Discussion Q&amp;A: The Cardiorenal Syndrome — Is It More Than the Sum of the Individual Components?</td>
<td>Moderator: Peter McCullough, MD, MPH</td>
<td></td>
</tr>
</tbody>
</table>

### SESSION #5  
**THE EFFECTS OF CANCER AND CANCER THERAPY ON METABOLIC DISORDERS**

**Chairs:** Derek LeRoith, MD PhD • Zachary Bloomgarden, MD

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker(s)</th>
<th>Affiliation</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:10 pm</td>
<td>Overview of The Interaction Between Obesity, Diabetes and Cancer Therapy</td>
<td>Derek LeRoith, MD, PhD</td>
<td></td>
</tr>
<tr>
<td>3:30 pm</td>
<td>The Effect of Tyrosine Kinase, PI3K/mTor Inhibitors on Metabolism</td>
<td>Emily Gallagher, MD</td>
<td></td>
</tr>
<tr>
<td>3:50 pm</td>
<td>Immunobiologics Effect on Diabetes: Type 1 And Type 2</td>
<td>Kevan Herold, MD</td>
<td></td>
</tr>
<tr>
<td>4:10 pm – 4:30 pm</td>
<td>Live Q&amp;A Panel Discussion</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### SESSION #5A  
**INSULIN RESISTANCE & T2D**

**Chairs:** Vivian Fonseca, MD

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker(s)</th>
<th>Affiliation</th>
</tr>
</thead>
<tbody>
<tr>
<td>4:30 pm</td>
<td>Important Role of Reduced Insulin Clearance in Pathogenesis of Type 2 Diabetes: Hypothesis and Experimental Confirmation in Man</td>
<td>Richard Bergman, PhD</td>
<td></td>
</tr>
<tr>
<td>4:50 pm – 5:00 pm</td>
<td>Live Q&amp;A Panel Discussion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Session #6: Pediatric Obesity Management</td>
<td>Chairs: Sonia Caprio, MD • Alan Sinaiko, MD</td>
<td></td>
<td></td>
</tr>
<tr>
<td>----------------------------------------</td>
<td>---------------------------------------------</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| 8:00 am                                | Pharmacotherapy in the Management of Pediatric Obesity  
A. Aaron Kelly, PhD |
| 8:20 am                                | Five-Year Outcomes of Gastric Bypass in Adolescents as Compared with Adults  
B. Thomas Inge, MD, PhD |
| 8:40 am                                | Sleeve Gastrectomy Impact on Cell Size and Genes from Adipose Tissue of Obese Adolescent Girls  
S. Sonia Caprio, MD |
| 9:00 am – 9:15 am                      | Live Q&A Panel Discussion |

| Session #7: What Should We Target to Treat Insulin Resistance? – Point-Counter-Point |
| Chairs: Richard Bergman, PhD • Bart Staels, PhD |
| 9:15 am                                | The Ceramide Pathway as a Target for Insulin Sensitization  
Phil Scherer, PhD |
| 9:35 am                                | Diacylglycerols and acetyl-CoA as a Therapeutic Targets for Insulin Resistance and Type 2 Diabetes  
G. Gerald Shulman, MD, PhD |
| 9:55 am – 10:15 am                      | Live Q&A Audience Vote/Panel Discussion |

| Session #8: LIPIDS |
| Chairs: Paul Jellinger, MD • Ronald Krauss, MD |
| 10:15 am                                | New Agents: PCSK9 siRNA (inclisiran) and Bempedoic Acid  
Kausik Ray, MD |
| 10:35 am                                | Triglycerides and CVD: Causal or Coincidental? Lessons from Recent Research  
Robert Rosenson, MD |
| 10:55 am                                | The Role of LP(a) & ANGPTL3 in Lipids Atherosclerosis and Cardiovascular Disease  
Norman Lepor, MD |
| 11:15 am – 11:35 am                      | Live Q&A Panel Discussion |

<table>
<thead>
<tr>
<th>11:35 am – 12:20 pm</th>
<th>PRODUCT THEATER  Non-CME</th>
</tr>
</thead>
</table>
| Potential Mechanisms Responsible for the Effects of Incretins on Atherosclerosis  
Supported by: Lilly  
Woody Corey, MD |

| Session #9: Insulin Focused Management of DM - Today and Tomorrow |
| Chairs: Vivian Fonseca, MD • Phil Scherer, PhD |
| 12:20 pm                                | Islet Cell Preservation & Replacement  
Jay Skyler, MD |
| 12:40 pm                                | Stem Cell Generated Human Islets- Rescue Diabetes Without a Device  
Ronald Evans, PhD |
| 1:00 pm                                 | State of the Art Insulin Delivery Systems  
George Grunberger, MD |
| 1:20 pm                                 | Tomorrow’s New Insulin Today  
Julia Rosenstock, MD |
| 1:40 pm – 2:00 pm                       | Live Q&A Panel Discussion |

| Session #10: Metabolism & 18 WCIRDC Joint Session: History of Insulin Resistance & Metabolism |
| Chair: Christos Mantzoros, MD, PhD |
| 2:00 pm                                | Introduction  
Christos Mantzoros, MD |
| 2:05 pm                                | Insulin Resistance and Cardiovascular Disease  
James Sowers, MD |
| 2:30 pm                                | Insulin resistance, NAFLD/NASH and CVD Risk  
Dimitri Mikhailidis, MD |
| 2:55 pm                                | Go with the Flow: Understanding Lipid Metabolism with Tracer Methods  
Gerald Watts, PhD |
| 3:20 pm – 3:40 pm                      | Live Q&A Panel Discussion |

| Session #11: Advanced Technologies & Genetics for Understanding & Managing IR & T2D |
| Chair: Daniel Einhorn, MD |
| 3:40 pm                                | Multiomics Analysis of IR vs IS Responses to Viral Infections, Exercise and Aging  
Michael Snyder, PhD |
| 4:00 pm                                | Continuous Glucose Monitoring for Precision Diets  
Tracey McLaughlin, MD |
| 4:20 pm                                | The Genetic Interrelationship Between T2D & Coronary Heart Disease  
Jerome Rotter, MD |
| 4:40 pm – 5:00 pm                      | Live Q&A Panel Discussion |

5:00 pm – 6:00 pm Day 2 Summary Session  
Sonia Caprio, MD • Vivian Fonseca, MD • George Grunberger, MD • Yehuda Handelsman, MD • Paul S. Jellinger, MD • Philipp E. Scherer, PhD
<table>
<thead>
<tr>
<th>SESSION #12</th>
<th>NAFLD/NASH</th>
<th>Chair: Sam Klein, MD</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 am</td>
<td>NASH - The Status of Diagnostics and Therapeutics</td>
<td>Christos Mantzoros, MD, PhD</td>
</tr>
<tr>
<td>8:20 am</td>
<td>The Sexually Dimorphic Nature of NASH May Impact on Disease Progression and Responses To Drugs</td>
<td>Bart Staels, PhD</td>
</tr>
<tr>
<td>8:40 am – 8:55 am</td>
<td>Live Q&amp;A Panel Discussion</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SESSION #13</th>
<th>Atherosclerosis Cardiovascular Disease</th>
<th>Chair: Norman Lepor, MD</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:55 am</td>
<td>Anti-Inflammatory Impact on Atherosclerosis: CVOT and Management Implications</td>
<td>Jorge Plutzky, MD</td>
</tr>
<tr>
<td>9:15 am</td>
<td>Impact of Non Statin Drugs On Plaque Formation and Atherosclerosis</td>
<td>Matthew Budoff, MD</td>
</tr>
<tr>
<td>9:35 am</td>
<td>GLP1ra and Atherosclerosis- Human Data at Last</td>
<td>Peter Reaven, MD</td>
</tr>
<tr>
<td>9:55 am – 10:15 am</td>
<td>Live Q&amp;A Panel Discussion</td>
<td></td>
</tr>
</tbody>
</table>

| 10:15 am – 11:00 am | PRODUCT THEATER  Non-CME |

| Jardiance® (empagliflozin) tablets: |
| A Review of Multiple Clinical Trials and Approved Indications |

Supported by: Boehringer Ingelheim/Lilly USA LLC

| 11:00 am     | The Influence of Dietary Carbs, Fat, And Quality on Ad Libitum Calorie Intake | Kevin Hall, PhD |
| 11:20 am     | Future of Obesity Pharmacotherapy: New Drugs and New Targets | Tim Garvey, MD |
| 11:40 am     | Effects of Bariatric Surgery on Cardiovascular Events | Phil Schauer, MD |
| 12:00 pm     | Does Intestinal Bypass Surgery Really Have Weight-Loss-Independent Therapeutic Metabolic Effects? | Sam Klein, MD |
| 12:20 pm – 12:40 pm | Live Q&A Panel Discussion | |

| 12:40 pm – 1:25 pm | PRODUCT THEATER  Non-CME |

Supported by: Abbott

| Speaker: TBD |

<table>
<thead>
<tr>
<th>SESSION #15</th>
<th>COVID-19 Pathophysiology and Advanced Management</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chairs: Richard Pratley, MD • Matthew Weir, MD</td>
<td></td>
</tr>
<tr>
<td>1:25 pm</td>
<td>Pathophysiological Basis &amp; Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection</td>
</tr>
<tr>
<td>1:45 pm</td>
<td>Sex Differences in Mortality from COVID-19 Pandemic</td>
</tr>
<tr>
<td>2:05 pm</td>
<td>The Role of Neutralizing Antibody Therapy in the Management of COVID-19</td>
</tr>
<tr>
<td>2:25 pm</td>
<td>Obesity &amp; COVID 19</td>
</tr>
<tr>
<td>2:45 pm – 3:05 pm</td>
<td>Live Q&amp;A Panel Discussion</td>
</tr>
</tbody>
</table>

| SESSION #16 | CME SYMPOSIUM |

<table>
<thead>
<tr>
<th>Emerging Standard of Care in the Prevention of Cardiovascular Morbidity and Mortality</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:05 pm</td>
</tr>
<tr>
<td>3:10 pm</td>
</tr>
<tr>
<td>3:30 pm</td>
</tr>
<tr>
<td>3:50 pm</td>
</tr>
<tr>
<td>4:10 pm</td>
</tr>
<tr>
<td>4:15 pm – 4:25 pm</td>
</tr>
<tr>
<td>4:25 pm – 4:45 pm</td>
</tr>
</tbody>
</table>

| 4:35 pm – 5:35 pm | DAY 3 SUMMARY SESSION |

Matthew J. Budoff, MD • Yehuda Handelsman, MD • Samuel Klein, MD • Norman E. Lepor, MD • Tracey L. McLaughlin, MD • Richard E. Pratley, MD • Matthew R. Weir, MD
### SESSION #17  
**CARDIOVASCULAR DISEASE AND INSULIN RESISTANCE**  
**Chairs:** Jorge Plutzky, MD • Robert Chilton, DO  

8:00 am | Insulin Resistance And Thrombotic Risk: Implications For Therapeutic Approaches To Vascular Disease | Peter Grant, MD  
8:20 am | Update of Recent CV Outcome Trials | Sanjay Kaul, MD  
8:40 am | The ACC’s Expert Consensus Decision Pathway: Improving Cardiovascular Outcomes in Type 2 Diabetes | Brendon Everett, MD  
9:00 am | The Future of Cardiometabolic Care is Here: Announcing Cardiometabolic Center Alliance | Mikhail Kosiborod, MD  
9:20 am – 9:40 am | Live Q&A Panel Discussion |  

### SESSION #18  
**CONTEMPORARY ASPECTS OF DIABETES MANAGEMENT**  
**Chairs:** Peter Grant, MD • Jaime Davidson, MD  

9:40 am | Managing Type 2 Diabetes to Prevent CVD-CKD: SGLT-2i, GLP-1RA or Initial Combination of Both? | Francesco Giorgino, MD, PhD  
10:00 am | Hypoglycemia Impact and Management | Vivian Fonseca, MD  
10:20 am | The Role of CGM in Diabetes Update toward 2021 | Richard Bergenstal, MD  
10:40 am – 10:59 am | Live Q&A Panel Discussion |  

10:59 am – 11:30 am | PRODUCT THEATER  Non-CME  
Atherosclerotic Cardiovascular Disease (ASCVD) in Diabetes: Identifying High Risk and the Importance of Reducing the Burden of Elevated LDL-C Levels  
Supported by: Novartis  
Yehuda Handelsman, MD  

### SESSION #19  
**OBESITY AND CVD IN TYPE 1 DIABETES**  
**Chairs:** George Grunberger, MD • Sonia Caprio, MD  

11:30 am | The Current Management of CV Risk factors in Type 1 Diabetes | Robert Eckel, MD  
11:50 am | DEBATE: SHOULD T2D MEDICATIONS WITH PROVEN CV BENEFITS BE USED IN T1D TO PREVENT ASCVD  
Yes | Richard Pratley, MD  
No | David Nathan, MD  
12:10 pm | Why Using T2D Medications with CVD Benefits is a Bad Idea for Type 1 Diabetes |  
12:30 pm – 12:50 pm | Live Q&A Audience Vote/Panel Discussion |  

### SESSION #20  
**THE KIDNEY IN DIABETES**  
**Chairs:** Christian Mende, MD • Ralph DeFronzo, MD  

12:50 pm | KDIGO- Diabetes CKD and Hypertension New Guidelines | Matthew Weir, MD  
1:10 pm | GLP1-RA and SGLT2i in the Treatment of Diabetic Nephropathy: What Does the Future Hold? | David Cherney, MD  
1:30 pm – 1:45 pm | Live Q&A Panel Discussion |  

1:45 pm – 2:30 pm | PRODUCT THEATER  Non CME  
VASCEPA (icosapent ethyl): Elevating the Standard of Care  
Supported by: Amarin  
Robert Busch, MD  

### SESSION #21  
**2:30 PM – 3:45 PM**  
**ABSTRACT – ORAL PRESENTATION**  
Zachary T. Bloomgarden, MD Chair • Philip Levy, MD • Daniel Einhorn, MD • George Grunberger, MD  
Abstracts are published in *Metabolism Journal*  
Editor-in-Chief: Christos S. Mantzoros, MD, PhD  

### SESSION #22  
**HEART FAILURE AND MANAGEMENT**  
**Chair:** Mikhail Kosiborod, MD  

3:45 pm | Lifestyle Modifications for Preventing and Treating Heart Failure | Monica Aggarwal, MD  
4:05 pm | All We Need to Know about HFpeF | Carolyn Lam, MD  
4:25 pm | Update on HFOT impact on Management - Sequencing vs Initial Combination of Medication | Javed Butler, MD  
4:45 pm – 5:05 pm | Live Q&A Panel Discussion |  

### 5:05 pm – 6:00 pm  
**DAY 4 SUMMARY SESSION**  
Ralph DeFronzo, MD • Daniel Einhorn, MD • Vivian Fonseca, MD • Yehuda Handelsman, MD • Mikhail Kosiborod, MD • Christian W. Mende, MD
Yehuda Handelsman, MD, FACP
FNLA, FASPC, MACE
Chair
Medical Director & Principal Investigator
The Metabolic Institute of America
Chair & Program Director, WCIRDC
Chair & Founder
International Committee for Insulin Resistance
Tarzana, California

Monica Aggarwal, MD
Associate Professor, Division of Cardiology
Director of Integrative Cardiology and Prevention
University of Florida/Shands Hospital
Gainesville, Florida

Richard M. Bergenstal, MD
Executive Director
International Diabetes Center
Saint Louis Park, Minnesota

Richard N. Bergman, PhD
Alfred Joy Feinstein Chair in Diabetes Research
Professor, Department of Biomedical Sciences
Cedars-Sinai
Director, Sports Spectacular Diabetes and Obesity Wellness and Research Center
Professor-in-Residence, Department of Medicine
Los Angeles, California

Deepak L. Bhatt, MD
MPH, FACC FAHA, FSCAI, FESC
Executive Director of Interventional Cardiologists
Brigham and Women’s Hospital Heart & Vascular Center
Professor of Medicine, Harvard Medical School
Boston, Massachusetts

Zachary T. Bloomgarden, MD, MACE
Clinical Professor
Department of Medicine
Icahn School of Medicine at Mount Sinai
New York, New York

Stefan Bornstein, PhD
Chair of Medicine, Internal Medicine,
University Clinic Dresden and
Dean of the transCampus initiative

Matthew J. Budoff, MD, FACC, FAHA
Professor of Medicine
UCLA School of Medicine
Endowed Chair of Preventive Cardiology
Lundquist Institute
Los Angeles, California

Javed Butler, MD, MPH, MBA
Patrick H. Lehman Chair in Cardiovascular Research
Professor and Chairman
Department of Medicine
University of Mississippi Medical Center
Jackson, Mississippi

Sonia Caprio, MD
Professor of Pediatric Endocrinology
Yale University School of Medicine
New Haven, Connecticut

David Cherney, MD
CM, PhD, FRCP
Senior Scientist,
Toronto General Hospital Research Institute
University Health Network
Associate Professor
Toronto, Ontario

Robert J. Chilton, DO, FACP
FACC, FAHA, MACOI, FASCAI
Professor of Medicine
Department of Medicine
Division of Cardiology
The University of Texas Health Science Center
San Antonio, Texas

Maria Rosa Costanzo, MD
FACC, FESC
Medical Director, Heart Failure Research, Advocate Heart Institute
Medical Director, Edward Hospital Center for Advanced Heart Failure
Naperville, Illinois

Kenneth Cusi, MD, FACP, FACE
Professor of Medicine
The University of Florida at Gainesville
Gainesville, Florida

Jaime A. Davidson, MD, FACP, MACE
Clinical Professor of Medicine
Division of Endocrinology
Diabetes and Metabolism
Touchstone Diabetes Research Center
The University of Texas Southwestern Medical Center
Dallas, Texas

Ralph A. DeFronzo, MD
Professor of Medicine
Chief, Diabetes Division
University of Texas Health Science Center at San Antonio (UTHSCSA)
San Antonio, Texas

Robert H. Eckel, M.D., FAHA, FACC
Professor of Medicine, Emeritus
Division of Endocrinology
Metabolism and Diabetes
Division of Cardiology
Charles A. Boettcher II Endowed Chair in Atherosclerosis, Emeritus
University of Colorado Anschutz Medical Campus
Past President, American Heart Association
President of Science and Medicine
American Diabetes Association
Denver Aurora, Colorado

Daniel Einhorn, MD, FACP, FACE
Chief, Diabetes and Endocrine Associates
Medical Director
Scripps Whittier Diabetes Institute
Clinical Professor, UCSD School of Medicine
La Jolla, California

Ronald M. Evans, PhD
Professor of Medicine
Director
Salk Institute for Biological Studies
La Jolla, California

Brendan M. Everett, MD, MPH
Associate Professor, Harvard Medical School
Division of Cardiovascular Medicine
Brigham and Women’s Hospital
Boston, Massachusetts

Vivian A. Fonseca, MD, FRCPC
Professor of Medicine and Pharmacology
Assistant Dean for Clinical Research
Tulane Tulane Alumni Chair in Diabetes, Section of Endocrinology
Tulane University Health Sciences Center
New Orleans, Louisiana

Emily Jane Gallagher, MD, PhD
Assistant Professor of Medicine, Endocrinology, Diabetes and Bone Disease
Associate Program Director for Internal Medicine Residency
Director of Research Track, Internal Medicine Residency Program
Department of Medicine
Icahn School of Medicine at Mount Sinai
New York, New York
W. Timothy Garvey, MD  
Butterworth Professor  
Department of Nutrition Sciences  
University of Alabama at Birmingham  
Director, UAB Diabetes Research Center  
Birmingham, Alabama  

Francesco Giorgino, MD, PhD  
President, Italian Society of Endocrinology (SIE)  
Professor of Endocrinology  
Chairman, Department of Emergency  
and Organ Transplantation  
Head, Section of Internal Medicine, Endocrinology, Andrology  
and Metabolic Diseases  
University of Bari Aldo Moro  
Chief, Division of Endocrinology  
University Hospital Policlinico Consorziale  
Milano, Italy  

Peter J. Grant, MD, FRCP, FMedSci  
Professor of Medicine  
Honorary Consultant Physician  
University of Leeds  
Leeds Teaching Hospitals NHS Trust  
Division of Cardiovascular & Diabetes Research  
LIGHT Laboratories  
Leeds, United Kingdom  

George Grunberger, MD  
FACP, MACE  
Chairman, Grunberger Diabetes Institute  
Clinical Professor, Internal Medicine and Molecular Medicine & Genetics  
Wayne State University School of Medicine  
Professor, Internal Medicine  
Oakland University William Beaumont  
School of Medicine  
Bloomfield Hills, Michigan  

Martha Gulati MD, MS, FACC, FAHA  
FASPC  
Editor-in-Chief, CardioSmart  
Phoenix, Arizona  

Kevin D. Hall, PhD  
Senior Investigator  
Integrative Physiology Section, Laboratory of Biological Modeling  
Bethesda, Maryland  

Kevan C. Herold, MD  
C.N.H. Long Professor of Immunobiology and of Medicine  
Deputy Director, Yale Center for Clinical Investigation  
Yale University  
New Haven, Connecticut  

Howard N. Hodies, MD  
Harry J. Bauer and Dorothy Bauer Rawlins Professor of Cardiology  
Professor of Medicine and Preventive Medicine  
Professor of Molecular Pharmacology and Toxicology  
Director, Atherosclerosis Research Unit  
Division of Cardiovascular Medicine  
Keck School of Medicine  
University of Southern California  

Thomas Ing, MD, PhD  
Professor of Surgery and Pediatrics  
Associate Surgeon-in-Chief  
Akers Endowed Chair and Director of Pediatric Surgery  
Children’s Hospital Colorado and University of Colorado  
Denver, Colorado  

Paul S. Jellinger, MD, MACE  
Professor of Clinical Medicine  
Voluntary Faculty  
University of Miami, Miller School of Medicine  
The Center for Diabetes & Endocrine Care  
Past President, AACE & ACE  
Hollywood, Florida  

Sanjay Kaul, MD, FACC, FAHA  
Professor of Medicine, Division of Cardiology  
Cedars-Sinai Medical Center  
David Geffen School of Medicine at UCLA  
Ronald Reagan UCLA Medical Center  
Fellow, American Heart Association  
Fellow, American College of Cardiology  
Los Angeles, California  

Aaron S. Kelly, PhD  
Professor, Department of Pediatrics  
Co-Director, Center for Pediatric Obesity Medicine  
University of Minnesota Medical School  
Minneapolis, Minnesota  

Samuel Klein, MD  
William H. Danforth Professor of Medicine and Nutritional Science  
Director, Center for Human Nutrition  
Washington University School of Medicine  
St. Louis, Missouri  

Marta Koch, PhD  
Editor-in-Chief  
The Lancet Diabetes & Endocrinology  
London, England  

Mikhail N. Kosiborod MD  
FACC, FAHA  
Professor of Medicine  
Saint Luke’s Mid America Heart Institute  
University of Missouri-Kansas City School of Medicine  
Kansas City, Missouri  

Ronald M. Krauss, MD  
Senior Scientist and Director  
Atherosclerosis Research  
Children's Hospital Oakland Research Institute  
Adjunct Professor  
Department of Medicine, UCSF  
Adjunct Professor  
Department of Nutritional Sciences  
University of California, Berkeley  
Berkeley, California  

Carolyn Lam Su Ping, MBBS, PhD  
MRCP, MS, FACC, FAMS, FESC  
Senior Consultant Cardiologist, National Heart Centre Singapore  
Professor, Duke-NUS Medical School  
Singapore  

Norman E. Lepor, MD  
FACC, FAHA, FSCAI  
Past President, California Chapter  
American College of Cardiology  
Clinical Professor of Medicine, Geffen School of Medicine-UCLA  
Attending Cardiologist  
Cedars-Sinai Heart Institute  
Co-director, Cardiovascular Imaging  
Westside Medical Imaging  
Director of Clinical Research  
Westside Medical Associates  
Los Angeles, California  

Derek LeRoith, MD, PhD, FACP  
Professor of Medicine  
Director of Research  
Division of Endocrinology  
Diabetes & Bone Disease  
Department of Medicine  
Icahn School of Medicine at Mt. Sinai  
New York, New York  

Philip Levy, MD, MACE  
Clinical Professor of Medicine, University of Arizona College of Medicine  
Endocrinologist  
Banner University Medical Group  
Phoenix, Arizona  

FACULTY 2020
Gina P. Lundberg, MD, FACC, FAHA  
Associate Professor of Medicine  
Emory University School of Medicine  
Clinical Director, Emory Women’s Heart Center  
Atlanta, Georgia

Christos S. Mantzoros, MD, DSc, PhD, h.c. multi.  
Professor of Medicine,  
Harvard Medical School and Boston University  
School of Medicine  
Chief of Endocrinology  
Diabetes and Metabolism  
Boston VA Healthcare System  
Director of Human Nutrition, Beth Israel Deaconess Medical Center  
Editor-in-Chief, Metabolism  
Clinical & Experimental  
Boston, Massachusetts

Nikolaus Marx, MD, FESC, FAHA  
Professor of Medicine / Cardiology  
Head of the Department of Internal Medicine  
University Hospital RWTH Aachen  
Aachen, Germany

Peter McCulloch, MD, MPH  
Professor of Medicine  
Baylor Heart and Vascular Institute  
Dallas, Texas

Tracy L. McLaughlin, MD, MS  
Professor of Medicine  
Division of Endocrinology  
Stanford University School of Medicine  
Stanford, California

Christian W. Mende, MD  
FACP, FACN, FASN, FASH  
Clinical Professor of Medicine  
University of California San Diego  
La Jolla, California

Erin Michos, MD, MHS  
Director of Women’s Cardiovascular Health  
Division of Cardiology  
Johns Hopkins University School of Medicine  
Clarksdale, Maryland

Dimitri Mikhailidis, MD  
Academic Head, Honorary Reader  
and Honorary Consultant in the  
Department of Molecular  
Pathology & Clinical Biochemistry  
Royal Free Hospital campus, University College  
London Medical School  
University College London (UCL), UK  
Visiting Professor at Robert Gordon University  
Aberdeen, Scotland

Geltrude Mingrone MD, PhD  
Associate Professor of Internal Medicine  
Catholic University of Rome, Italy  
Professor of Diabetes and Nutrition  
King’s College London  
London, United Kingdom

David M. Nathan, MD  
Director, Massachusetts General Hospital Diabetes Center  
Professor of Medicine  
Harvard Medical School  
Boston, Massachusetts

Ajay Nirula, MD, PhD  
Vice President, Immunology  
Eli Lilly & Co  
San Diego, California

Neha J. Pogidipati, MD, MPH  
Assistant Professor of Medicine  
Division of Cardiology  
Duke Clinical Research Institute  
Durham, North Carolina

Jorge Plutzky, MD  
Director, Preventive Cardiology  
Cardiovascular Medicine  
Brigham and Women’s Hospital  
Harvard Medical School  
Boston, Massachusetts

Richard E. Pratley, MD  
Samuel E. Crockett Chair in Diabetes Research,  
Senior Investigator and Diabetes Program Lead  
AdvantHealth Translational Research Institute  
Johns Hopkins University School of Medicine  
Orlando, Florida

Eric Ravussin, PhD  
Boyd Professor  
Director Nutrition Obesity Research Center  
Douglas L. Gordon Chair in  
Diabetes and Metabolism  
Pennington Biomedical Research Center  
Louisiana State University  
Baton Rouge, Louisiana

Kausik Ray, BS(hons), MBChB, MD,  
MPHil (Cantab), FRCP (Lon), FRCP (Ed), FACC, FESC, FAHA  
Professor of Public Health/Consultant Cardiologist  
Deputy Director of The Imperial Clinical Trials  
Unit Head of Commercial Trials  
Department of Public Health and Primary Care  
School of Public Health, Imperial College  
Chief Clinical Officer and  
Head of Trials – Discover Now  
NIHR ARC National Lead of  
Cardiovascular Disease  
EAS President Elect  
London, United Kingdom

Peter Reaven, MD  
Professor of Clinical Medicine  
University of Arizona  
Phoenix, Arizona

Robert Rosenson, MD  
Professor of Medicine (Cardiology)  
Mount Sinai Icahn School of Medicine  
Director, Cardiometabolics Unit  
Mount Sinai Heart  
New York, New York

Julio Rosenstock, MD  
Director, Dallas Diabetes Research Center  
Medical City Dallas  
Clinical Professor of Medicine  
University of Texas Southwestern Medical Center  
Dallas, Texas

Jerome I. Rotter, MD  
Investigator, The Lundquist Institute  
Director, Institute for Translational Genomics  
and Population Sciences,  
Harbor-UCLA Medical Center  
Professor of Pediatrics, Medicine  
and Human Genetics  
David Geffen School of Medicine at UCLA  
Los Angeles, California

Arun J. Sanyal, MBBS, MD  
Professor of Medicine  
Physiology and Molecular Pathology  
Division of Gastroenterology  
Hepatology and Nutrition  
VCU Medical Center  
Director, Education Core, CCTR  
Virginia Commonwealth University  
Richmond, Virginia
The International Committee for Insulin Resistance gratefully acknowledges:

**Unrestricted Educational Grants**

- Abbott • Amarin

**Premier Educator**

- AstraZeneca

**Leader Educator**

- Lilly • Merck

**Major Educator**

- Novo Nordisk

**Educator**

- Zealand Pharma

**Corporate Support**

- Esperion • Amgen

**Opal Level**

- Abbott • Amarin

**Emerald Level**

- Boehringer Ingelheim/Lilly USA • Novartis

---

**Faculty 2020**

**Philip R. Schauer MD**  
FACS, FASMB  
Mary Kay and Terrell Brown/Harris J. Chustz  
Chair  
Professor of Metabolic Surgery  
Pennington Biomedical Research Center  
at Louisiana State University  
Baton Rouge, Louisiana

**Philip E. Scherer, PhD**  
Touchstone Diabetes Center  
The University of Texas Southwestern  
Medical Center  
Dallas, Texas

**Gerald I. Shulman, MD, PhD**  
George R. Cowgill Professor of Medicine  
(Endocrinology)  
Professor of Medicine and Cellular &  
Molecular Physiology  
Co-Director Yale Diabetes Research Center  
Yale University School of Medicine  
New Haven, Connecticut

**Alan R. Sinaiko, MD**  
Professor, Department of Pediatrics  
Division of Pediatric Nephrology  
University of Minnesota Medical School  
Minneapolis, Minnesota

**Jay S. Skyler, MD, MACP**  
Professor of Medicine  
Pediatrics and Psychology  
Deputy Director, Diabetes Research Institute  
University of Miami  
Miami, Florida

**Michael P. Snyder, PhD**  
Professor and Chair of Genetics  
Director, Center for Genomics  
and Personalized Medicine  
Stanford University School of Medicine  
Stanford, California

**James Sowers, MD**  
Director, Diabetes and Cardiovascular Center  
Professor of Physiology  
Pharmacology and Medicine  
Dalton Cardiovascular Research Center  
University of Missouri  
School of Medicine  
Columbia, Missouri

**Bart Staels, PhD**  
Full Professor, University of Lille  
Director of Inserm UMR1011  
European Genomics Institute for Diabetes  
Institute Pasteur de Lille  
Lille, France

**Katherine R. Tuttle, MD**  
FASN, FACP, FNKF  
Executive Director for Research  
Providence Health Care  
Professor of Medicine, University of Washington  
Co-Principal Investigator, Institute of  
Translational Health Sciences

**Muthiah Vaduganathan, MD, MPH**  
Cardiologist, Brigham and Women’s Hospital,  
Harvard Medical School  
Boston, Massachusetts

**Gerald F Watts DSc, PhD, DM, FRACP, FRCP**  
Winthrop Professor Cardio-Metabolic and  
Internal Medicine  
Royal Perth Hospital  
University of Western Australia  
Perth, Australia

**Matthew R. Weir, MD**  
Professor and Chief  
Division of Nephrology  
Department of Medicine  
University of Maryland School of Medicine  
Baltimore, Maryland

**Paul Zimmet AO, MD, PhD**  
Professor of Diabetes  
Monash University  
Melbourne, Australia

---

**The International Committee for Insulin Resistance gratefully acknowledges**

- Esperion • Amgen

- Abbott • Amarin

- Boehringer Ingelheim/Lilly USA

- Lilly • Novartis

---

**THE INTERNATIONAL COMMITTEE FOR INSULIN RESISTANCE GRATIFYING ACKNOWLEDGES**

**PREMIER EDUCATOR**

- AstraZeneca

**LEADER EDUCATOR**

- Abbott • Amarin

**MAJOR EDUCATOR**

- Lilly • Merck

**EDUCATOR**

- Novo Nordisk

**CORPORATE SUPPORT**

- Esperion • Amgen

**OPAL LEVEL**

- Abbott • Amarin

**EMERALD LEVEL**

- Boehringer Ingelheim/Lilly USA • Novartis
ATTENDANCE IS FREE!
Free Registration • Free CME ABIM / MOC
www.WCIR.ORG/registration
Email: info@tmioa.com  |  To register by phone: 818-342-1889

CME ACCREDITATION
For CME questions related to WCIRDC, please contact our CME Coordinator Renee Asp at renee@aspencmehelp.com

This activity was planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint providership of PESI Inc. and the Metabolic Endocrine Education Foundation (MEEF). PESI Inc. is accredited by the ACCME to provide continuing medical education for physicians.

AMA PRA DESIGNATION STATEMENT
PESI Inc. has designated this live activity for a maximum of 33.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

MOC POINTS WITH ABIM
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn MOC points of Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Total qualifying MOC credits TBA.

FAMILY PHYSICIANS
Application for CME credit has been filed with the American Academy of Family Physicians.

INTERNATIONAL CME
International Physicians are formally eligible for AMA PRA Category 1 Credit™.

PHYSICIAN ASSISTANTS
AAPA accepts Category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA PRA Category 1 Credit™ for the PRA from organizations accredited by ACCME.

NURSES
For the purpose of re-certification, the American Nurses Credentialing Center accepts AMA PRA Category 1 Credit™ issued by organizations accredited by the ACCME (Accreditation Council for Continuing Medical Education) for attendance at structured learning activities.

CA NURSES
Aspen CME Services is approved by the California Board of Registered Nursing, provider number CEP14739, designated the 18th WCIRDC for contact hours - total hours TBA.

PHARMACISTS
For the purpose of re-certification, the American Council of Pharmacy Education accepts AMA PRA Category 1 Credit™ issued by organizations accredited by the ACCME (Accreditation Council for Continuing Medical Education) for attendance at structured learning activities.

CDE
The National Certification Board for Diabetes Educators recognizes courses sponsored by PESI Inc. as approved ACCME provider. Total qualifying continuing education hours TBA.

REGISTERED DIETITIANS
For the purpose of re-certification, the Commission on Dietetic Registration recognizes courses accredited with AMA PRA Category 1 Credit™.

SATISFACTORY COMPLETION FOR CREDITS
All attendees must have completed and turned in a course attendance/evaluation form prior to leaving the conference. Each session claimed for credit must be attended in its entirety.
WCIRDC PARTNERS & ENDORSING ORGANIZATIONS

Media Partners

- Metabolism (Elsevier)
- The Lancet Diabetes & Endocrinology
- Healio: Cardiology Today & Endocrine Today
- Bentham Science
- Cardiovascular Endocrinology & Metabolism (Wolters Kluwer)
- CN1699
- ConferenceLocate.com
- Diabetes & Vascular Disease Research (Sage)
- Diabetes in Control
- Elsevier
- Endocrine Web

- Endocrinology Advisor
- Hindawi
- Journal of Diabetes
- MIMS
- MJH Life Sciences (American Journal of Managed Care & HCPLive Network)
- PharmaVoice
- Physician’s Weekly
- Sage Publishing
- VenueDir
- Vessel Plus

Participating Organizations

- American Diabetes Association (ADA)
- American Society for Preventive Cardiology (ASPC)
- American Association of Diabetes Educators (AADE)
- American Society for Nutrition (ASN)
- American Society of Endocrine Physician Assistants (ASEPA)
- Association of Diabetes Care & Education Specialists (ADCES)
- California Chapter of the American College of Cardiology (CAACC)
- Endocrine Nurses Society (ENS)
- Familial Hypercholesterolemia (FH) Foundation

- International Academy of Cardiology (IAC)
- International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO)
- Israel Endocrine Society (IES)
- Pacific Lipid Association
- Point of Care Network (POCN)
- Society for Vascular Surgery (SVS)
- World Obesity Federation

FOR ADDITIONAL INFORMATION ON
Registration | Support | Exhibits
(818) 432-1889 | info@tmioa.com | www.WCIR.ORG

Save the Date • 19th WCIRDC • December 2–4, 2021
Hilton Universal City I Hotel Los Angeles, California